Your browser doesn't support javascript.
loading
Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
Merola, E; Pascher, A; Rinke, A; Bartsch, D K; Zerbi, A; Nappo, G; Carnaghi, C; Ciola, M; McNamara, M G; Zandee, W; Bertani, E; Marcucci, S; Modica, R; Grützmann, R; Fazio, N; de Herder, W; Valle, J W; Gress, T M; Fave, G Delle; de Pretis, G; Perren, A; Wiedenmann, B; Pavel, M E.
Afiliação
  • Merola E; Department of Medicine 1, Division of Endocrinology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. elettra.merola@apss.tn.it.
  • Pascher A; Department of Gastroenterology, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy. elettra.merola@apss.tn.it.
  • Rinke A; Department of Surgery, Charité Universitätsmedizin, Berlin, Germany.
  • Bartsch DK; Klinik für Allgemein, Viszeral- und Transplantationschirurgie, Universitätsklinikum Münster, Münster, Germany.
  • Zerbi A; Department of Gastroenterology, University Hospital Gießen and Marburg, Marburg, Germany.
  • Nappo G; Department of Visceral, Thoracic and Vascular Surgery, Philipps-University Marburg, Marburg, Germany.
  • Carnaghi C; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Ciola M; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • McNamara MG; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Zandee W; Oncology Unit, Bolzano Central Hospital, Bolzano, Italy.
  • Bertani E; Department of Surgery, Bolzano Central Hospital, Bolzano, Italy.
  • Marcucci S; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Modica R; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Grützmann R; Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands.
  • Fazio N; Department of Internal Medicine, Division of Endocrinology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • de Herder W; Division of Gastrointestinal Surgery, European Institute of Oncology IRCCS, Milan, Italy.
  • Valle JW; Department of Surgery 2, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy.
  • Gress TM; Department of Clinical Medicine and Surgery, Endocrinology Unit, University Federico II, Naples, Italy.
  • Fave GD; Department of Surgery, University Medical Center Erlangen, Erlangen, Germany.
  • de Pretis G; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology IEO, IRCCS, Milan, Italy.
  • Perren A; Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands.
  • Wiedenmann B; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Pavel ME; Department of Gastroenterology, University Hospital Gießen and Marburg, Marburg, Germany.
Ann Surg Oncol ; 29(9): 5568-5577, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35583694
BACKGROUND: Surgery with radical intent is the only potentially curative option for entero-pancreatic neuroendocrine tumors (EP-NETs) but many patients develop recurrence even after many years. The subset of patients at high risk of disease recurrence has not been clearly defined to date. OBJECTIVE: The aim of this retrospective study was to define, in a series of completely resected EP-NETs, the recurrence-free survival (RFS) rate and a risk score for disease recurrence. PATIENTS AND METHODS: This was a multicenter retrospective analysis of sporadic pancreatic NETs (PanNETs) or small intestine NETs (SiNETs) [G1/G2] that underwent R0/R1 surgery (years 2000-2016) with at least a 24-month follow-up. Survival analysis was performed using the Kaplan-Meier method and risk factor analysis was performed using the Cox regression model. RESULTS: Overall, 441 patients (224 PanNETs and 217 SiNETs) were included, with a median Ki67 of 2% in tumor tissue and 8.2% stage IV disease. Median RFS was 101 months (5-year rate 67.9%). The derived prognostic score defined by multivariable analysis included prognostic parameters, such as TNM stage, lymph node ratio, margin status, and grading. The score distinguished three risk categories with a significantly different RFS (p < 0.01). CONCLUSIONS: Approximately 30% of patients with EP-NETs recurred within 5 years after radical surgery. Risk factors for recurrence were disease stage, lymph node ratio, margin status, and grading. The definition of risk categories may help in selecting patients who might benefit from adjuvant treatments and more intensive follow-up programs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos Idioma: En Ano de publicação: 2022 Tipo de documento: Article